Last reviewed · How we verify
Epirubicin plus Cyclophosphamide
Epirubicin and cyclophosphamide are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, commonly used as a combination regimen in breast cancer treatment.
Epirubicin and cyclophosphamide are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, commonly used as a combination regimen in breast cancer treatment. Used for Breast cancer (neoadjuvant or adjuvant treatment), Early-stage and locally advanced breast cancer.
At a glance
| Generic name | Epirubicin plus Cyclophosphamide |
|---|---|
| Also known as | EC |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Chemotherapy combination (anthracycline + alkylating agent) |
| Target | DNA (topoisomerase II for epirubicin; DNA alkylation for cyclophosphamide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin is a topoisomerase II inhibitor and anthracycline that intercalates into DNA and generates reactive oxygen species, while cyclophosphamide is an alkylating agent that cross-links DNA strands. Together, this combination (EC regimen) provides synergistic cytotoxic effects against rapidly dividing cancer cells. This regimen is frequently used as neoadjuvant or adjuvant therapy in breast cancer.
Approved indications
- Breast cancer (neoadjuvant or adjuvant treatment)
- Early-stage and locally advanced breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity
- Hemorrhagic cystitis
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy (NA)
- A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: